journal article·2019-04-26Open access

Plasmon-Enhanced Pan-Microbial Pathogen Inactivation in the Cavitation Regime: Selectivity Without Targeting

Mina Nazari, Min Xi, Mark Aronson, Oliver Mcrae, Mi K. Hong, Suryaram Gummuluru, Allyson E. Sgro, James C. Bird, Lawrence D. Ziegler, Christopher Gillespie, Kathleen Souza, Nhung Nguyen, Robert M. Smith, Edward Silva, Ayako Miura, Shyamsunder Erramilli, Björn M. Reinhard

ACS Applied Nano Materials· Volume 2· Issue 4

Abstract

Pan-microbial inactivation technologies that do not require high temperatures, reactive chemical compounds, or UV radiation could address gaps in current infection control strategies and provide efficient sterilization of biologics in the biotechnological industry. Here, we demonstrate that femtosecond (fs) laser irradiation of resonant gold nanoparticles (NPs) under conditions that allow for E-field mediated cavitation and shockwave generation achieve an efficient plasmon-enhanced photonic microbial pathogen inactivation. We demonstrate that this NP-enhanced, physical inactivation approach is effective against a diverse group of pathogens, including both enveloped and nonenveloped viruses, and a variety of bacteria and mycoplasma. Photonic inactivation is wavelength-dependent and in the absence of plasmonic enhancement from NPs, negligible levels of microbial inactivation are observed in the near-infrared (NIR) at 800 nm. This changes upon addition of resonant plasmonic NPs, which provide a strong enhancement of inactivation of viral and bacterial contaminants. Importantly, the plasmon-enhanced 800 nm femtosecond (fs)-pulse induced inactivation was selective to pathogens and was obtained without specific targeting of the NPs to the pathogens. No measurable damage was observed for antibodies included as representative biologics under identical conditions.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Laser-Ablation Synthesis of Nanoparticles · Gold and Silver Nanoparticles Synthesis and Applications · Nonlinear Optical Materials Studies

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Microbiology, Boston University School of Medicine, Boston, Massachusetts 02118, United States

Immunogen, 830 Winter Street, Waltham, Massachusetts 02451, United States

Process Solutions, MilliporeSigma, Bedford, Massachusetts 01730, United States

Takeda Pharmaceuticals, 35 Landsdowne Street, Cambridge, Massachusetts 02139, United States

Funding

MilliporeSigma

References (59)

Show source-provided references
1. European Medicines AgencyGuideline on the sterilisation of the medicinal product, active substance, excipient and primary container.In EMA/CHMP/CVMP/QWP/850374/2015, London, UK, 2016.
2. Ensor, L. A. In Current Issues Regarding Sterility Assurance Submissions for Sterile Generic Drug Products,GPhA/FDA Fall Technical Conference; U.S. Food and Drug Administration: 2011.
3. 10.1208/s12249-010-9503-z10.1208/s12249-010-9503-z ↗
4. 10.1016/S0960-8524(02)00008-110.1016/S0960-8524(02)00008-1 ↗
5. Chang J. C. · Applied and environmental microbiology. · 1985 · 49 · 136110.1128/aem.49.6.1361-1365.1985 ↗
6. 10.1016/j.watres.2005.10.03010.1016/j.watres.2005.10.030 ↗
7. Jornitz M. W. · 2008
8. 10.1016/j.biologicals.2010.03.00210.1016/j.biologicals.2010.03.002 ↗
9. Whyte W. · PDA Journal of Pharmaceutical Science and Technology · 1982 · 36 · 102
10. 10.4155/pbp.13.6110.4155/pbp.13.61 ↗
11. Kuriyel R. · 2000
12. 10.4103/0970-2113.6361110.4103/0970-2113.63611 ↗
13. 10.1093/nar/gkv13610.1093/nar/gkv136 ↗
14. Bloom M. E. · Journal of Virology · 1980 · 35 · 83610.1128/jvi.35.3.836-843.1980 ↗
15. Tsen S.-W. D. · 201610.1088/978-1-6817-4353-0 ↗
16. 10.1117/1.JBO.19.1.01500810.1117/1.JBO.19.1.015008 ↗
17. 10.1109/JSTQE.2015.249892010.1109/JSTQE.2015.2498920 ↗
18. 10.1117/1.360077110.1117/1.3600771 ↗
19. Neves-Petersen M. T. · 2012
20. 10.1117/1.327547710.1117/1.3275477 ↗
21. 10.1021/ph400018s10.1021/ph400018s ↗
22. 10.1364/OE.17.00253810.1364/OE.17.002538 ↗
23. 10.1021/jp312475h10.1021/jp312475h ↗
24. 10.1038/s41598-017-12377-510.1038/s41598-017-12377-5 ↗
25. 10.1186/1423-0127-19-6210.1186/1423-0127-19-62 ↗
26. 10.1088/0022-3727/47/31/31540210.1088/0022-3727/47/31/315402 ↗
27. 10.1021/acsami.6b0016110.1021/acsami.6b00161 ↗
28. 10.1002/smll.20130243410.1002/smll.201302434 ↗
29. 10.1128/AEM.02001-0710.1128/AEM.02001-07 ↗
30. 10.2147/IJN.S2401910.2147/IJN.S24019 ↗
31. 10.1002/adfm.20170025610.1002/adfm.201700256 ↗
32. 10.1039/C5NR03442F10.1039/C5NR03442F ↗
33. 10.1039/C6NR05376A10.1039/C6NR05376A ↗
34. 10.1038/lsa.2017.210.1038/lsa.2017.2 ↗
35. 10.1103/PhysRevB.94.24542610.1103/PhysRevB.94.245426 ↗
36. 10.1364/OE.23.00196710.1364/OE.23.001967 ↗
37. 10.1016/j.biomaterials.2011.11.06210.1016/j.biomaterials.2011.11.062 ↗
38. 10.1021/nl302200w10.1021/nl302200w ↗
39. 10.1364/JOSAB.13.00048110.1364/JOSAB.13.000481 ↗
40. 10.1016/j.cplett.2004.04.05610.1016/j.cplett.2004.04.056 ↗
41. 10.1109/3.77721510.1109/3.777215 ↗
42. 10.1021/jp412409u10.1021/jp412409u ↗
43. 10.1053/jhin.2000.079410.1053/jhin.2000.0794 ↗
44. 10.1186/1743-422X-11-2010.1186/1743-422X-11-20 ↗
45. 10.1088/2399-1984/aadf9d10.1088/2399-1984/aadf9d ↗
46. 10.1021/jp057170o10.1021/jp057170o ↗
47. 10.1088/1361-648X/aa60f310.1088/1361-648X/aa60f3 ↗
48. 10.1007/s12274-017-1483-910.1007/s12274-017-1483-9 ↗
49. 10.1016/j.jphotochemrev.2013.06.00110.1016/j.jphotochemrev.2013.06.001 ↗
50. 10.1128/genomeA.01578-1610.1128/genomeA.01578-16 ↗
51. 10.1038/nbt1109-98710.1038/nbt1109-987 ↗
52. 10.1038/nri274710.1038/nri2747 ↗
53. 10.5731/pdajpst.2014.0095910.5731/pdajpst.2014.00959 ↗
54. DePalma A. · Genetic Engineering & Biotechnology News · 2010 · 30 · 38
55. 10.2471/BLT.11.03021110.2471/BLT.11.030211 ↗
56. 10.1002/adom.20140050510.1002/adom.201400505 ↗
57. 10.1021/jacs.6b1214310.1021/jacs.6b12143 ↗
58. 10.1021/cm303661d10.1021/cm303661d ↗
59. 10.1002/1521-3773(20010601)40:11<2004::AID-ANIE2004>3.0.CO;2-510.1002/1521-3773(20010601)40:11<2004::AID-ANIE2004>3.0.CO;2-5 ↗